Skip to Main Content

View Public Comments for Anticancer Chemotherapy for Colorectal Cancer

Use the browser below to select the Comment Period for which you would like to view the comments for the selected document. You can use the alphabetical links above the results table to jump to comments submitted by a commenter whose last name starts with that letter. Select the ‘Expand All Comments’ link to view all the full comments, and click the ‘Collapse All Comments’ link to view only the abstract for all comments. Select the ‘More’ link in the Comment to view the full text of the specific comment in a new window.
The first (earliest) set of comments are displayed by default in the Public Comment Results section. To view additional Comment Periods, use the radio button options and select the "Submit" button.
An asterisk (*) indicates a required field.

      Select one period.


[23 Comments]
Page 1 of 1
First character of titleCommenterComment Information
B
Bitkower, Jay Title: President
Organization: Action to Cure Kidney Cancer
Date: 11/27/2004
Comment:

Dear CMS,

On behalf of Action to Cure Kidney Cancer (ACKC), I am writing in support of the CMS proposed policy to cover the costs, in clinical trials, of off-label uses for cancer drugs that are already approved for colorectal cancer More opens in new window

C
Cassidy, George Title: CEO - Medical Director
Organization: High Tech Medical Imaging
Date: 12/07/2004
Comment:

I am a Nuclear Medicine Physician and Radiologist and I have been practicing for approximately thirty years. I have found PET imaging oncology to be the most helpful and definitive modality when combined with CT fusion for evaluation More opens in new window

C
Chudacek, Debra Organization: Cancer Leadership Council
Date: 12/23/2004
Comment:

December 23, 2004

Mark A. McClellan, M.D., Ph.D.AdministratorCenters for Medicare & Medicaid ServicesDepartment of Health & Human Services200 Independence Avenue, S.W.Room 314-G – HHH Bldg.Washington, D.C. 20201

Re: Draft Decision Memo for More opens in new window

C
Comis, MD, Robert Title: President and Chair
Organization: Coalition of National Cancer Cooperative Groups
Date: 12/30/2004
Comment:

The Coalition of National Cancer Cooperative Groups is a non-profit organization dedicated to increasing awareness and participation in cancer clinical trials. Our membership represents approximately 8,000 physician/researchers who comprise the More opens in new window

D
Davenport-Ennis, Nancy Title: CEO
Organization: National Patient Advocate Foundation
Date: 12/22/2004
Comment:

National Patient Advocate Foundation (NPAF) is a patient organization whose mission is to seek improved access to and reimbursement for health care services through both policy and legislative reform at the state and federal levels. Our mission More opens in new window

D
Davenport-Ennis, Nancy Title: President and CEO
Organization: National Patient Advocate Foundation
Date: 12/02/2004
Comment:

As you know, the National Patient Advocate Foundation (NPAF) is a non-profit healthcare organization dedicated to the mission of creating avenues of patient access to insurance coverage for evolving therapies, therapeutic agents, and devices More opens in new window

D
Dougherty, James Date: 12/31/2004
Comment:

The Alliance of Dedicated Cancer Centers
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
City of Hope National Medical Center
Dana-Farber Cancer Institute
Fox Chase Cancer Center
H. Lee More opens in new window

H
Hoegstedt, Johan Title: Vice President, Specialty Brands
Organization: AstraZeneca Pharmaceuticals, LP
Date: 12/29/2004
Comment:

AstraZeneca Pharmaceuticals ("AstraZeneca") appreciates the opportunity to submit comments on the draft national coverage determination (NCD) for Anticancer Chemotherapy for Colorectal Cancer (CAG-00179N), released on November 1, 2004. More opens in new window

H
Hohneker, MD, John Title: Vice President, Oncology Medical Affairs & Service
Organization: Novartis Oncology
Date: 12/01/2004
Comment:

I am pleased to submit the following comments on behalf of the oncology business unit of Novartis Pharmaceuticals Corporation ("Novartis"), an affiliate of Novartis Corporation, regarding the above referenced draft coverage decision memorandum More opens in new window

J
Jamieson-Baker, Patti Title: President
Organization: Assocation of Community Cancer Centers
Date: 12/01/2004
Comment:

The Association of Community Cancer Centers (ACCC) respectfully urges you to extend the comment period on the Centers for Medicare and Medicaid Services' (CMS) proposed coverage decision memorandum for anticancer chemotherapy for colorectal More opens in new window

J
Jamieson-Baker, MSSW, MBA, Patti Title: President
Organization: Association of Community Cancer Centers
Date: 12/30/2004
Comment:

The Association of Community Cancer Centers (ACCC) and the 12 undersigned state oncology societies appreciate this opportunity to comment on the Centers for Medicare and Medicaid Services’ (CMS) draft coverage decision memorandum for More opens in new window

J
Johnson, David Title: President
Organization: American Society of Clinical Oncology
Date: 12/23/2004
Comment:

The American Society of Clinical Oncology (ASCO) submits these comments in response to the Centers for Medicare and Medicaid Services (CMS) proposed coverage determination on the use of oxaliplatin (Eloxatin®), irinotecan (Camptosar®), More opens in new window

L
Lucas, W. Charles Title: Senior Assistant General Counsel
Organization: Phizer
Date: 12/28/2004
Comment:

Pfizer Inc. respectfully submits these comments on the Draft Decision Memo for Anticancer Chemotherapy for Colorectal Cancer, dated November 1, 2004 ("Draft Decision").

Pfizer is a research-based, global pharmaceutical company More opens in new window

M
Moore, Walter Title: Vice President, Government Affairs
Organization: Genentech, Incorporate
Date: 12/22/2004
Comment:

Genentech is pleased to respond to the Centers for Medicare & Medicaid Services’ (CMS) request for comments on the draft decision memorandum for Anticancer Chemotherapy for Colorectal Cancer. Genentech is among the world’s leading biotechnology More opens in new window

O
O'Leary, Kevin Title: Vice President, Customer Planning & Contracting
Organization: Hoffmann-LaRoche, Inc.
Date: 12/30/2004
Comment:

Roche Laboratories Inc. ("Roche"), a research- based pharmaceutical company, submits the following comments in response to the draft national coverage decision (NCD) for anticancer chemotherapy for colorectal cancer (CAG-00179N). As the More opens in new window

O
O'Neill, Hugh Title: Vice President, U.S. Integrated Health Care Market
Organization: Sanofi-Synthelabo, Inc.
Date: 12/29/2004
Comment:

Sanofi-Aventis 1/ appreciates the opportunity to comment on the draft national coverage decision (NCD) for anticancer chemotherapy for colorectal cancer (CAG-00179N). As the manufacturer of oxaliplatin (Eloxatin®), we have been engaged actively More opens in new window

Q
Quirk, James Title: Senior VP
Organization: Memorial Sloan-Kettering Cancer Center
Date: 12/31/2004
Comment:

The Alliance of Dedicated Cancer Centers
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
City of Hope National Medical Center
Dana-Farber Cancer Institute
Fox Chase Cancer More opens in new window

R
Roach, Nancy Title: Director
Organization: Colorectal Cancer Coalition
Date: 12/31/2004
Comment:

Thank you for the opportunity to comment on the Draft Decision Memo for Anticancer Chemotherapy for Colorectal Cancer (CAG-00179N). 

I am responding on behalf of the Colorectal Cancer Coalition, More opens in new window

S
Smith, Richard Title: Senior Vice President
Organization: PhRMA
Date: 12/23/2004
Comment:

The Pharmaceutical Research and Manufacturers of America ("PhRMA") is pleased to submit these comments in response to the Draft Coverage Decision Memorandum for Anticancer Chemotherapy for Colorectal Cancer (#CAG-00179N), posted on the Centers More opens in new window

S
Smith, Richard Title: Senior Vice President
Organization: Pharmaceutical Research and Manufacturers of America
Date: 11/30/2004
Comment:

The purpose of this letter is to request an extension of the public comment period on a proposed CMS decision memorandum concerning Medicare national coverage of anticancer chemotherapy for colorectal cancer (CAG-00179N).

The Pharmaceutical More opens in new window

S
Stevens, Charles A. Organization: Cell Therapeutics, Inc.
Date: 12/16/2004
Comment:

I am writing to comment on the November 1, 2004 draft National Coverage Decision (NCD) on off label indications for certain colorectal anti-cancer therapies (CAG # 00179N). Cell Therapeutics, Inc. (CTI) is a biotechnology company located in More opens in new window

W
Werner, Michael Title: Chief of Policy
Organization: Biotechnology Industry Organization
Date: 12/01/2004
Comment:

The Biotechnology Industry Organization (BIO) respectfully requests an extension of the comment period on the Centers for Medicare and Medicaid Services' (CMS) draft coverage decision
memorandum for anticancer chemotherapy for colorectal More opens in new window

W
Werner, Michael Title: Chief of Policy
Organization: BIO - Biotechnology Industry Organization
Date: 12/23/2004
Comment:

The Biotechnology Industry Organization (BIO) appreciates this opportunity to comment on the Centers for Medicare and Medicaid Services' (CMS) draft coverage decision memorandum for anticancer chemotherapy for colorectal cancer (CAG-00179N). BIO More opens in new window

Page 1 of 1
85